Harnessing IDO inhibitors to optimize cancer immunotherapy
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-12 · 398 (12) · 16797-16815
DOI: 10.1007/s00210-025-04445-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 17.07.2025. Verfasst von Safia Obaidur Rab und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia. Hauptthemen laut MEDLINE: Indoleamine-Pyrrole 2,3,-Dioxygenase, Neoplasms, Immunotherapy, Enzyme Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 94 Literaturangaben. Gefördert von: King Khalid University.
Abstract (Originalsprache)
The tumor microenvironment (TME) is rich in immunosuppressive molecules that collectively hinder effective anti-tumor immune responses and promote tumor progression. Among the most prominent are transforming growth factor-beta (TGF-β), which suppresses T cell proliferation, promotes the differentiation of regulatory T cells, and remodels the extracellular matrix to exclude immune cells. Enzymes such as indoleamine 2,3-dioxygenase 1 and 2 (IDO1, IDO2) and tryptophan 2,3-dioxygenase (TDO) degrade tryptophan into kynurenine metabolites, leading to T cell anergy, apoptosis, and expansion of regulatory T cells through activation of the aryl hydrocarbon receptor. Recently, cancer immunotherapy has seen remarkable progress with the advent of IDO inhibitors, which target a critical pathway through which tumors evade immune responses to their advantage. This review outlines the mechanisms by which IDO contributes to tumor-induced immune suppression, examining the associated signaling pathways that facilitate this process. It thoroughly reviews the potential of IDO inhibitors as monotherapy or in combination with conventional chemotherapy, assessing their clinical implications and safety profiles. The discussion includes perspectives on overcoming resistance mechanisms and optimizing therapeutic outcomes through combination strategies. Ultimately, this document aims to enhance the understanding of IDO's role in cancer immunopathogenesis, advancing patient management within the oncological landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
- Department of Applied Sciences, University of Technology, Baghdad, Iraq.
- Department of Biotechnology and Genetics, School of Sciences, JAIN (deemed to be University), Bangalore, Karnataka, India.
- Chandigarh Pharmacy College, Chandigarh Group of Colleges, Mohali-140307, Jhanjheri, Punjab, India.
- School of Applied and Life Sciences, Division of Research and Innovation, Uttaranchal University, Dehradun, Uttarakhand, India.
- Department of Biology, College of Education for Pure Sciences, University of Anbar, Ramadi, Anbar, 31001, Iraq. hussin.riyadh@uoanbar.edu.iq.
Förderung
- King Khalid University
Zitieren
APA
Rab, S. O., Jaafar, H. K., Jabir, M. S., Malathi, H., Devi, S., Pramanik, A., Al-Hetty, H. R. A. K., Alnajar, M. J., Jawad, S. F., & Mustafa, Y. F. (2025). Harnessing IDO inhibitors to optimize cancer immunotherapy. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(12), 16797-16815. https://doi.org/10.1007/s00210-025-04445-9
Vancouver
Rab SO, Jaafar HK, Jabir MS, Malathi H, Devi S, Pramanik A, et al. Harnessing IDO inhibitors to optimize cancer immunotherapy. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(12):16797-16815. doi:10.1007/s00210-025-04445-9
BibTeX
@article{Rab2025,
author = {Rab, Safia Obaidur and Jaafar, Huda K and Jabir, Majid S and Malathi, H and Devi, Seema and Pramanik, Atreyi and Al-Hetty, Hussein Riyadh Abdul Kareem and Alnajar, Mohammed Jawad and Jawad, Sabrean F and Mustafa, Yasser Fakri},
title = {Harnessing IDO inhibitors to optimize cancer immunotherapy},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
volume = {398},
number = {12},
pages = {16797--16815},
doi = {10.1007/s00210-025-04445-9}
}
EUVIMED